about
Transcriptional regulation of chemokine expression in ovarian cancerRole of chemokine network in the development and progression of ovarian cancer: a potential novel pharmacological target.Inherited determinants of ovarian cancer survival.Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass.The role of chemoattractant receptors in shaping the tumor microenvironment.Biological significance of prolactin in gynecologic cancers.Protein biomarkers of ovarian cancer: the forest and the treesNetwork-based survival analysis reveals subnetwork signatures for predicting outcomes of ovarian cancer treatment.Skeletal Muscle Depletion and Markers for Cancer Cachexia Are Strong Prognostic Factors in Epithelial Ovarian Cancer.CD192 gene variant and susceptibility to cervical cancer: a meta analysisTLR9 ligation in pancreatic stellate cells promotes tumorigenesisThe identification of age-associated cancer markers by an integrative analysis of dynamic DNA methylation changes.Diagnostic significance of serum eotaxin-1 level in gastric cancer patientsExpression and prognostic significance of CCL11/CCR3 in glioblastoma.Targeting CCL11 in the treatment of ovarian cancer.Chemokines: key players in cancer progression and metastasis.CCL11-induced eosinophils inhibit the formation of blood vessels and cause tumor necrosis.CCL11 promotes angiogenic activity by activating the PI3K/Akt pathway in HUVECs.Inflammatory cytokines are associated with response and prognosis in patients with esophageal cancer.Relevance of CCL3/CCR5 axis in oral carcinogenesis.The "Aging Factor" Eotaxin-1 (CCL11) Is Detectable in Transfusion Blood Products and Increases with the Donor's Age.Different Cytokine and Chemokine Expression Patterns in Malignant Compared to Those in Nonmalignant Renal Cells.CCR3 induced-p42/44 MAPK activation protects against staurosporine induced-DNA fragmentation but not apoptosis in airway smooth muscle cells.Is Eotaxin-1 a serum and urinary biomarker for prostate cancer detection and recurrence?
P2860
Q26825361-15069B3C-6404-4407-A21E-1954A814C3C8Q33559560-8A722E6C-7F26-4C80-979D-37E0FF83BBA6Q33638923-5B930A6A-4DAA-49F2-BD2B-FB1EF640FCD0Q33862961-D4522927-2AE7-4415-BAEF-1ACF0CE19236Q33993124-BDF72866-FFD9-4F2F-9A44-52210696C935Q34052860-E25C1572-1C03-42A3-94B3-8FA43B0326A2Q34634143-E0A241D9-2256-43EA-9DE7-08A863476251Q34649455-717D8E02-10BF-4594-94A6-AFD73D0CCFDBQ35803334-294AB620-96B1-4E35-B44C-903D1E2E59D0Q35959197-5B4CD360-E4E5-417B-ABED-4A2DECA74C99Q36286020-BB0D5BBA-3954-4E7E-B303-60E4DC67DB5EQ36656824-CBBE8C24-BE6F-4B93-86F6-1C9E0330294FQ37260649-4F793EF5-D5AF-408D-8601-CFDC2734CF14Q37362728-557BCC98-F507-43AD-B320-FF6A5C8F2EFBQ37670242-279CE0EB-9E0B-4CA2-BC88-4428D302B533Q37881763-8EA0FCD4-1DAB-4234-9FD4-239843CF8535Q38771642-41F299A4-D345-4929-B673-B37E97C9C9A1Q38917035-522317A9-5F07-435E-B766-4DFAEDBB37FBQ41471150-B2DC5189-A1FB-4CE1-B234-3AB715002225Q41612583-B5E71F92-DAA2-45F1-AB42-59EAC4F9798BQ47563544-B3AB3436-F6BF-4E27-A272-3276B7191482Q52836563-B116BBCC-6E04-443D-B42D-0F884D291482Q53162585-50BE980C-60EF-4FE0-848C-AEFF1CD19792Q53372753-06EE6146-4855-4519-94B8-A53516AC4BFE
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 07 April 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Role of eotaxin-1 signaling in ovarian cancer
@en
Role of eotaxin-1 signaling in ovarian cancer.
@nl
type
label
Role of eotaxin-1 signaling in ovarian cancer
@en
Role of eotaxin-1 signaling in ovarian cancer.
@nl
prefLabel
Role of eotaxin-1 signaling in ovarian cancer
@en
Role of eotaxin-1 signaling in ovarian cancer.
@nl
P2093
P2860
P1476
Role of eotaxin-1 signaling in ovarian cancer
@en
P2093
Adele M Marrangoni
Anna E Lokshin
Brian M Nolen
Elieser Gorelik
Jeffrey R Marks
Marta E Szajnik
Miroslaw J Szczepanski
Peng Cheng
Vera Levina
P2860
P304
P356
10.1158/1078-0432.CCR-08-2024
P407
P577
2009-04-07T00:00:00Z